Great Pipeline Overview put together by Mauibound
Post# of 104
(Total Views: 1117)
Posted On: 02/10/2017 10:20:09 PM
Great Pipeline Overview put together by Mauibound
AMDX owns the rights to MSPreciseÒ, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro TestÒ) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
· Operations of Amarantus Diagnostics and Theranostics Health have consolidated into Avant Diagnostics (OTCQB:AVDX) · Diagnostics pipeline in Alzheimer's disease (LymPro Test™), Ovarian cancer (OvaDx™) and Multiple Sclerosis (MSPrecise™) added to already available Breast cancer test (TheraLinkÒ) in Maryland-based CLIA/CAP facility
SCOTTSDALE, AZ, SAN FRANCISCO, CA and GAITHERSBERG, MD – May 11, 2016 - Avant Diagnostics, Inc. ("Avant" (OTCQB: AVDX), an innovative molecular diagnostics company, today announced it has completed the acquisition of Amarantus Diagnostics, Inc. ("AMDX" , a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. ("AMBS" (OTCQX: AMBS), and the business of Theranostics Health, Incorporated ("THI" . In connection with the acquisition of THI, Avant intends to appoint Glenn Hoke, PhD, President & CEO of THI, as Chief Scientific Officer. In connection with the acquisition of AMDX, Gerald Commissiong, President & CEO of AMBS, has been appointed to the Board of Directors of Avant.
Under the terms of the agreement for the acquisition of AMDX, Avant has acquired all of the outstanding shares of common stock of AMDX for an aggregate of 80,000,000 shares of Avant common stock, subject to issuance of additional shares upon the occurrence of certain future events. Under the terms of the agreement for the acquisition of THI, Avant acquired the assets and operations of THI for an aggregate of 25,000,000 shares of Avant common stock. Each share of Avant common stock issued to AMBS and THI will be subject to an eighteen (18) month lock-up, subject to certain exceptions.
Avant will initially look to grow THI's pharma services revenue by expanding existing relationships with pharmaceutical customers, particularly in the area of immune-oncology, and moving into new areas in neuro-immunology, specifically Alzheimer's disease. In parallel, the Company will be preparing for CLIA validation studies for the Company's proprietary diagnostic tests in the areas of Alzheimer's disease (LymPro Test™), ovarian cancer (OvaDx™) and multiple sclerosis (MSPrecise™). THI's TheraLinkÒ assay is currently available under CLIA. Overall, the Company has within its CLIA/CAP certified facility the ability to perform microarray, Western blot, flow cytometry, ELISA and next-gen sequencing assays.
"The closing of these acquisitions marks a pivotal moment for Avant," said Gregg A. Linn, President & CEO of Avant. "We have simultaneously expanded our product pipeline into new areas of oncology with the acquisition of THI's business, as well as moved into neurology with the acquisition of AMDX. Moreover we have acquired the appropriate CLIA/CAP infrastructure required to commercialize our pipeline while also gaining access to a growing pharma services revenue stream with the very same sales, distribution channels, commercial relationships and overall scientific focus (immunology and cell cycle biology) required for successful introduction of our additional proprietary assets to the pharma services market. We now have a clear path towards building a robust diagnostic laboratory testing business while also furthering our proprietary tests towards market entry."
Post-merger Avant Pipeline for CLIA and Pharma Services
1. TheraLinkÒ Assay includes phospho-activation markers for known drug targets of over 30 FDA-approved therapies for treating breast cancer patients that are likely responders to specific treatment regimens. In addition, the TheraLinkÒ Assay panel includes other biomarkers that have utility in directing patients to clinical trials involving new investigational therapeutic agents as likely responders. Research programs and clinical trials are underway at leading institutions to validate the TheraLinkÒ Assay panel for managing cancer treatment decisionmaking in other clinically significant areas such as colorectal, lung, pancreatic and ovarian cancer. TheraLinkÒ is available now under CLIA and additional phospho-activation marker testing services are provided to the pharmaceutical industry. 2. LymPro Test™ neuroimmunology-based flow cytometry assay for Alzheimer's Disease (AD), offers an early, accurate, and scalable diagnostic result for physicians seeking to provide the best information and treatment plan for patients from the earliest stages of this devastating disease. AD diagnosis has an approximately 30% misdiagnosis rate. AD costs the healthcare system approximately $200 B in direct costs per year, and these costs are expected to exceed $1.2T by 2050 according to the current spending and demographics trajectories. 3. OvaDxÒ immuno-oncology diagnostic assay is a protein-based test, potentially representing a significant improvement in the screening and diagnosis for ovarian cancer. OvaDx offers the possibility to make a clear improvement to the current diagnostic standard that generates over $2B in sales annually by substantially improving the accuracy of diagnosis, and allowing for a more effective therapeutic triaging and intervention strategy. Longer term, the assay could become a much-needed early screening tool for all women as part of a standard screening paradigm. 4. MSPrecise™ neuroimmunology-basednext-gen sequencing (NGS) diagnostic assay for multiple sclerosis (MS) offers a potentially highly accurate and actionable result that will substantially improve upon the high misdiagnosis rate of this degenerative disease. More specifically, MS has an approximately 40% misdiagnosis rate, meaning that improving diagnostic accuracy will be a key driver to adopt more effective therapeutic strategies that will reduce costs for payers and improve outcomes for patients. About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in biomarker tests that are based on querying large panels of proteins with exquisite precision. Avant's first test, OvaDxÒ, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDxÒ is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDxÒ indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDxÒ. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.
http://ir.avantdiagnostics.com/all-sec-filing...010436.pdf
A TGIF Cheers!!!
AMDX owns the rights to MSPreciseÒ, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro TestÒ) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro).
Avant Diagnostics Simultaneously Completes Acquisitions of Amarantus Diagnostics and Theranostics Health
· Operations of Amarantus Diagnostics and Theranostics Health have consolidated into Avant Diagnostics (OTCQB:AVDX) · Diagnostics pipeline in Alzheimer's disease (LymPro Test™), Ovarian cancer (OvaDx™) and Multiple Sclerosis (MSPrecise™) added to already available Breast cancer test (TheraLinkÒ) in Maryland-based CLIA/CAP facility
SCOTTSDALE, AZ, SAN FRANCISCO, CA and GAITHERSBERG, MD – May 11, 2016 - Avant Diagnostics, Inc. ("Avant" (OTCQB: AVDX), an innovative molecular diagnostics company, today announced it has completed the acquisition of Amarantus Diagnostics, Inc. ("AMDX" , a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. ("AMBS" (OTCQX: AMBS), and the business of Theranostics Health, Incorporated ("THI" . In connection with the acquisition of THI, Avant intends to appoint Glenn Hoke, PhD, President & CEO of THI, as Chief Scientific Officer. In connection with the acquisition of AMDX, Gerald Commissiong, President & CEO of AMBS, has been appointed to the Board of Directors of Avant.
Under the terms of the agreement for the acquisition of AMDX, Avant has acquired all of the outstanding shares of common stock of AMDX for an aggregate of 80,000,000 shares of Avant common stock, subject to issuance of additional shares upon the occurrence of certain future events. Under the terms of the agreement for the acquisition of THI, Avant acquired the assets and operations of THI for an aggregate of 25,000,000 shares of Avant common stock. Each share of Avant common stock issued to AMBS and THI will be subject to an eighteen (18) month lock-up, subject to certain exceptions.
Avant will initially look to grow THI's pharma services revenue by expanding existing relationships with pharmaceutical customers, particularly in the area of immune-oncology, and moving into new areas in neuro-immunology, specifically Alzheimer's disease. In parallel, the Company will be preparing for CLIA validation studies for the Company's proprietary diagnostic tests in the areas of Alzheimer's disease (LymPro Test™), ovarian cancer (OvaDx™) and multiple sclerosis (MSPrecise™). THI's TheraLinkÒ assay is currently available under CLIA. Overall, the Company has within its CLIA/CAP certified facility the ability to perform microarray, Western blot, flow cytometry, ELISA and next-gen sequencing assays.
"The closing of these acquisitions marks a pivotal moment for Avant," said Gregg A. Linn, President & CEO of Avant. "We have simultaneously expanded our product pipeline into new areas of oncology with the acquisition of THI's business, as well as moved into neurology with the acquisition of AMDX. Moreover we have acquired the appropriate CLIA/CAP infrastructure required to commercialize our pipeline while also gaining access to a growing pharma services revenue stream with the very same sales, distribution channels, commercial relationships and overall scientific focus (immunology and cell cycle biology) required for successful introduction of our additional proprietary assets to the pharma services market. We now have a clear path towards building a robust diagnostic laboratory testing business while also furthering our proprietary tests towards market entry."
Post-merger Avant Pipeline for CLIA and Pharma Services
1. TheraLinkÒ Assay includes phospho-activation markers for known drug targets of over 30 FDA-approved therapies for treating breast cancer patients that are likely responders to specific treatment regimens. In addition, the TheraLinkÒ Assay panel includes other biomarkers that have utility in directing patients to clinical trials involving new investigational therapeutic agents as likely responders. Research programs and clinical trials are underway at leading institutions to validate the TheraLinkÒ Assay panel for managing cancer treatment decisionmaking in other clinically significant areas such as colorectal, lung, pancreatic and ovarian cancer. TheraLinkÒ is available now under CLIA and additional phospho-activation marker testing services are provided to the pharmaceutical industry. 2. LymPro Test™ neuroimmunology-based flow cytometry assay for Alzheimer's Disease (AD), offers an early, accurate, and scalable diagnostic result for physicians seeking to provide the best information and treatment plan for patients from the earliest stages of this devastating disease. AD diagnosis has an approximately 30% misdiagnosis rate. AD costs the healthcare system approximately $200 B in direct costs per year, and these costs are expected to exceed $1.2T by 2050 according to the current spending and demographics trajectories. 3. OvaDxÒ immuno-oncology diagnostic assay is a protein-based test, potentially representing a significant improvement in the screening and diagnosis for ovarian cancer. OvaDx offers the possibility to make a clear improvement to the current diagnostic standard that generates over $2B in sales annually by substantially improving the accuracy of diagnosis, and allowing for a more effective therapeutic triaging and intervention strategy. Longer term, the assay could become a much-needed early screening tool for all women as part of a standard screening paradigm. 4. MSPrecise™ neuroimmunology-basednext-gen sequencing (NGS) diagnostic assay for multiple sclerosis (MS) offers a potentially highly accurate and actionable result that will substantially improve upon the high misdiagnosis rate of this degenerative disease. More specifically, MS has an approximately 40% misdiagnosis rate, meaning that improving diagnostic accuracy will be a key driver to adopt more effective therapeutic strategies that will reduce costs for payers and improve outcomes for patients. About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in biomarker tests that are based on querying large panels of proteins with exquisite precision. Avant's first test, OvaDxÒ, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDxÒ is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDxÒ indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDxÒ. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.
http://ir.avantdiagnostics.com/all-sec-filing...010436.pdf
A TGIF Cheers!!!
(1)
(0)Avant Diagnostics, Inc. (AVDX) Stock Research Links
Scroll down for more posts ▼